Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
January 28th, 2025
Solid Quarter for Somnomed; Revenue up 20% to $28.5 Million
Read More
December 20th, 2024
Positive Phase I Final Data from Cynata Therapeutics
Read More
December 5th, 2024
Dimerix: Unmet Need Drives Positive Changes to Trial Endpoints in FSGS
Read More
July 10th, 2024
Botanix Raises $70 million with Sofdra FDA Approval
Read More
November 3rd, 2023
Neuren Pharmaceuticals – Strong DAYBUE Sales in September Quarter at US$67 million
Read More
October 10th, 2023
Acquisition Targets for Australian Biotech Sector (Cogstate)
Read More
October 3rd, 2023
Acquisition Targets for Australian Biotech Sector (Anteris Technologies)
Read More
May 1st, 2023
Pharmaxis Phase II Trial Results Approaching
Read More
May 1st, 2023
Immuron – Sales Start to Rebound Strongly
Read More
April 6th, 2023
Imugene - Nine Clinical Programs to Advance in 2023
Read More
April 6th, 2023
Imricor Focuses on Dedicated iCMR Labs
Read More
April 6th, 2023
Chimeric Therapeutics - Viral Vector Manufacturing Achieved
Read More
April 6th, 2023
Anteris Technologies - Early Feasibility Study to Start Ahead of 1,000 Patient Pivotal Trial
Read More
April 6th, 2023
Aroa Biosurgery - Manufacturing Capacity to Reach NZ$150 Million
Read More
March 17th, 2023
From Benchtop to the Clinic - Stunning Success for Neuren Pharmaceuticals
Read More
February 24th, 2023
Pharmaxis: A Re-Rating Approaching?
Read More
February 24th, 2023
Opthea - Full Recruitment to Trigger Results Countdown
Read More
February 24th, 2023
Neuren Pharmaceuticals - FDA Decision on Trofinetide Approaching
Read More
February 24th, 2023
EBR Systems - Pivotal Results Due Q2
Read More
February 24th, 2023
Cogstate Acquisition Discussions Halted
Read More
Pages
1
2
